There has not yet been any evidence to suggest that the $5 billion worldwide juggernaut, otherwise known as the market for drug-eluting stents, had any risk of imploding over the increased risk of clots following implantation. However, as we predicted, the occurence of late-stage thrombosis associated with drug-eluting stents is having a de facto impact on this market, even if [...]
bookmark to
